In a groundbreaking study published in the prestigious journal Cancer Discovery, researchers from the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have elucidated a critical biological mechanism underlying the variable efficacy of immunotherapy in bladder cancer patients. This discovery sheds light on the interplay between systemic inflammation and immune suppression within tumors, revealing potential new avenues for enhancing cancer treatment outcomes.
Bladder cancer treatment has been revolutionized by the advent of immune checkpoint inhibitors—therapies designed to unleash the immune system’s ability to attack cancer cells. Despite their promise, these treatments yield durable responses in only a subset of patients, leaving many with limited benefit. Previously, elevated blood markers of inflammation, notably C-reactive protein (CRP), have been correlated with poor prognosis, yet the precise connection linking systemic inflammation and tumor immune evasion remained obscure.
The research team, led by Dr. Nina Bhardwaj, Director of Immunotherapy at Mount Sinai, alongside Dr. Matthew Galsky and Dr. Diego Chowell, employed cutting-edge single-cell genomics and RNA sequencing analyses to construct the most comprehensive atlas of bladder tumors reported to date. This atlas enabled unprecedented insight into the cellular and molecular landscape of bladder tumors and their associated immune infiltrates.
Their findings pinpoint a distinct subset of macrophages within the tumor microenvironment characterized by the expression of SPP1, a gene implicated in modulating immune responses. These SPP1-positive macrophages were found to correlate strongly with elevated levels of systemic CRP and interleukin-6 (IL-6), a pro-inflammatory cytokine also detectable in peripheral blood. Importantly, these macrophages exhibited pronounced immunosuppressive properties, actively inhibiting cytotoxic T cell activity essential for anti-tumor immunity.
Mechanistically, the team demonstrated that IL-6 signaling pathways within the tumor microenvironment foster the expansion and activation of these SPP1+ macrophages. The cascade culminates in a potent dampening of T cell-mediated tumor killing, effectively neutralizing the therapeutic actions of checkpoint inhibitors. This phenomenon offers a critical explanation for why some bladder cancers remain refractory to immunotherapy despite systemic treatment.
Contrastingly, the researchers identified a separate subset of macrophages marked by CXCL9 expression, which appear to enhance T cell activation and promote more robust anti-cancer immune responses. This dichotomy highlights the complex balancing act within tumors between immune activation and suppression, governed by the heterogeneous populations of myeloid cells.
This research builds a direct link between systemic inflammatory biomarkers—long used clinically as non-specific indicators—and specific immune processes inside tumors. The implication is profound: routine blood tests assessing CRP and IL-6 levels might soon serve as predictive tools for immunotherapy responsiveness. Patients with heightened systemic inflammation may harbor microenvironments hostile to immune attack, requiring alternative or combination therapeutic strategies.
Dr. Chowell emphasized that this study not only decodes the biological basis of immune dysfunction in bladder cancer but also underscores the broader importance of inflammatory signaling in shaping tumor immunity. The inflammatory milieu serves as a window into the tumor’s immunological status, offering a biomarker-driven framework to guide precision oncology.
The translational potential extends beyond mere diagnostics. By targeting the IL-6–SPP1+ macrophage axis, future therapies may reprogram or inhibit these immunosuppressive cells, restoring T cell function and amplifying the efficacy of existing checkpoint blockade treatments. Novel drug candidates focusing on IL-6 signaling are already in clinical pipeline phases and may benefit from patient stratification rooted in these biomarkers.
Clinically, these insights empower oncologists to stratify patients more effectively, tailoring treatment according to their inflammatory and immunological profiles. Patients with inherent resistance patterns could be offered early intervention through combination therapies or enrolled in clinical trials exploring anti-inflammatory adjuncts to immunotherapy.
The research group continues to delve deeper into the biology of SPP1+ macrophages to unravel the molecular triggers behind their suppressive capabilities and how tumor-intrinsic factors modulate their function. Their ongoing studies aim to unlock therapeutic vulnerabilities and enhance the armamentarium against bladder cancer.
This landmark study was supported by significant funding from the National Institutes of Health, reflective of its innovative nature and clinical relevance. Through the integration of immunology, computational biology, and translational medicine, the team exemplifies the future of cancer research—one that bridges systemic biology with tumor microenvironment intricacies.
In summary, the newly uncovered IL-6–SPP1+ macrophage–CRP axis represents a pivotal checkpoint in bladder cancer immunity. By connecting peripheral inflammation with intra-tumoral immune suppression, this research opens promising pathways to better predict, and ultimately improve, patient responses to immunotherapy, potentially transforming treatment paradigms not only in bladder cancer but also in other inflammation-associated malignancies.
Subject of Research: Cells
Article Title: A tumor-promoting inflammatory SPP1+ macrophage—IL-6—CRP axis drives immune dysfunction in bladder cancer
News Publication Date: 18-Mar-2026
Web References: http://dx.doi.org/10.1158/2159-8290.CD-25-1774
References: Published in Cancer Discovery, DOI: 10.1158/2159-8290.CD-25-1774
Keywords: Cancer immunotherapy, Cancer treatments, Bladder cancer, Immunotherapy resistance, SPP1+ macrophages, IL-6 signaling, C-reactive protein, Tumor microenvironment, Immune suppression, Immune checkpoint inhibitors
